Stockreport

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Aura Biosciences, Inc.  (AURA) 
PDF Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDAData Expected Mid-2024 from Ongoing [Read more]